CUL4A Ubiquitin Ligase Is an Independent Predictor of Overall Survival in Pancreatic Adenocarcinoma

Cancer Genomics Proteomics. 2024 Mar-Apr;21(2):166-177. doi: 10.21873/cgp.20438.

Abstract

Background/aim: Pancreatic ductal adenocarcinoma (PDAC) is an aggressive malignancy with dismal prognosis. Genomic instability due to defects in cell-cycle regulation/mitosis or deficient DNA-damage repair is a major driver of PDAC progression with clinical relevance. Deregulation of licensing of DNA replication leads to DNA damage and genomic instability, predisposing cells to malignant transformation. While overexpression of DNA replication-licensing factors has been reported in several human cancer types, their role in PDAC remains largely unknown. We aimed here to examine the expression and prognostic significance of the DNA replication-licensing factors chromatin licensing and DNA replication factor 1 (CDT1), cell-division cycle 6 (CDC6), minichromosome maintenance complex component 7 (MCM7) and also of the ubiquitin ligase regulator of CDT1, cullin 4A (CUL4A), in PDAC.

Materials and methods: Expression levels of CUL4, CDT1, CDC6 and MCM7 were evaluated by immunohistochemistry in 76 formalin-fixed paraffin-embedded specimens of PDAC patients in relation to DNA-damage response marker H2AX, clinicopathological parameters and survival. We also conducted bioinformatics analysis of data from online available databases to corroborate our findings.

Results: CUL4A and DNA replication-licensing factors were overexpressed in patients with PDAC and expression of CDT1 positively correlated with H2AX. Expression of CUL4A and CDT1 positively correlated with lymph node metastasis. Importantly, elevated CUL4A expression was associated with reduced overall survival and was an independent indicator of poor prognosis on multivariate analysis.

Conclusion: Our findings implicate CUL4A, CDT1, CDC6 and MCM7 in PDAC progression and identify CUL4A as an independent prognostic factor for this disease.

Keywords: CDC6; CDT1; CUL4A; DNA-replication licensing; H2AX; MCM; Pancreatic ductal adenocarcinoma; cell cycle.

MeSH terms

  • Adenocarcinoma* / genetics
  • Cell Cycle Proteins / genetics
  • Cullin Proteins / genetics
  • Cullin Proteins / metabolism
  • DNA
  • Genomic Instability
  • Humans
  • Ligases / genetics
  • Pancreatic Neoplasms* / genetics
  • Ubiquitin

Substances

  • Ligases
  • Ubiquitin
  • Cell Cycle Proteins
  • DNA
  • CUL4A protein, human
  • Cullin Proteins